Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2011

Open Access 01-12-2011 | Research article

Expression pattern of class I histone deacetylases in vulvar intraepithelial neoplasia and vulvar cancer: a tissue microarray study

Authors: Nicolas Samartzis, Patrick Imesch, Konstantin J Dedes, Eleftherios P Samartzis, André Fedier, Daniel Fink, Rosmarie Caduff, Mathias K Fehr

Published in: BMC Cancer | Issue 1/2011

Login to get access

Abstract

Background

Epigenetic regulation is an important mechanism leading to cancer initiation and promotion. Histone acetylation by histone deacetylases (HDACs) represents an important part of it. The development of HDAC inhibitors has identified the utility of HDACs as a therapeutic target. Little is known about the epigenetic regulation of vulvar intraepithelial neoplasia (VIN) and vulvar squamous cell cancer (VSCC). In this study, the expression of class I HDACs (HDAC 1, 2 and 3) was compared in a series of VIN and VSCC tissues.

Methods

A tissue micro array (TMA) with specimens from 106 patients with high-grade VIN and 59 patients with vulvar cancer was constructed. The expression of HDACs 1, 2 and 3 were analyzed with immunohistochemistry (IHC). The nuclear expression pattern was evaluated in terms of intensity and percentage of stained nuclei and was compared between vulvar preinvasive lesions and vulvar cancer.

Results

HDAC 2 expression was significantly higher in VIN than in VSCC (p < 0.001, Fisher's test). Also, 88.7% (n = 94/106) of VIN samples and only 54.5% (n = 31/57) of VSCC samples were scored at the maximum level. Conversely, HDAC 3 expression was significantly higher in VSCC (93%, 53/57) compared to VIN (73.6%, 78/106, p = 0.003), whereas only a small difference in the expression of HDAC 1 was found between these two entities of vulvar neoplasia.

Conclusions

These results suggest that epigenetic regulation plays a considerable role in the transformation of VIN to invasive vulvar neoplasia.
Appendix
Available only for authorised users
Literature
1.
Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ: Cancer statistics, 2009. CA Cancer J Clin. 2009, 59 (4): 225-249. 10.3322/caac.20006.CrossRefPubMed
2.
Howe HL, Wingo PA, Thun MJ, Ries LA, Rosenberg HM, Feigal EG, Edwards BK: Annual report to the nation on the status of cancer (1973 through 1998), featuring cancers with recent increasing trends. J Natl Cancer Inst. 2001, 93 (11): 824-842. 10.1093/jnci/93.11.824.CrossRefPubMed
3.
Judson PL, Habermann EB, Baxter NN, Durham SB, Virnig BA: Trends in the incidence of invasive and in situ vulvar carcinoma. Obstet Gynecol. 2006, 107 (5): 1018-1022. 10.1097/01.AOG.0000210268.57527.a1.CrossRefPubMed
4.
Moore DH: Chemotherapy and radiation therapy in the treatment of squamous cell carcinoma of the vulva: Are two therapies better than one?. Gynecol Oncol. 2009, 113 (3): 379-383. 10.1016/j.ygyno.2009.01.004.CrossRefPubMed
5.
Ghurani GB, Penalver MA: An update on vulvar cancer. Am J Obstet Gynecol. 2001, 185 (2): 294-299. 10.1067/mob.2001.117401.CrossRefPubMed
6.
Manchana T, Ittiwut C, Mutirangura A, Kavanagh JJ: Targeted therapies for rare gynaecological cancers. Lancet Oncol. 11 (7): 685-693.
7.
Bernstein BE, Meissner A, Lander ES: The mammalian epigenome. Cell. 2007, 128 (4): 669-681. 10.1016/j.cell.2007.01.033.CrossRefPubMed
8.
9.
Kouzarides T: Chromatin modifications and their function. Cell. 2007, 128 (4): 693-705. 10.1016/j.cell.2007.02.005.CrossRefPubMed
10.
Glozak MA, Rogers MB: Retinoic acid- and bone morphogenetic protein 4-induced apoptosis in P19 embryonal carcinoma cells requires p27. Exp Cell Res. 2001, 268 (2): 128-138. 10.1006/excr.2001.5281.CrossRefPubMed
11.
Glozak MA, Seto E: Histone deacetylases and cancer. Oncogene. 2007, 26 (37): 5420-5432. 10.1038/sj.onc.1210610.CrossRefPubMed
12.
Halkidou K, Gaughan L, Cook S, Leung HY, Neal DE, Robson CN: Upregulation and nuclear recruitment of HDAC1 in hormone refractory prostate cancer. Prostate. 2004, 59 (2): 177-189. 10.1002/pros.20022.CrossRefPubMed
13.
Song J, Noh JH, Lee JH, Eun JW, Ahn YM, Kim SY, Lee SH, Park WS, Yoo NJ, Lee JY, et al: Increased expression of histone deacetylase 2 is found in human gastric cancer. APMIS. 2005, 113 (4): 264-268. 10.1111/j.1600-0463.2005.apm_04.x.CrossRefPubMed
14.
Huang BH, Laban M, Leung CH, Lee L, Lee CK, Salto-Tellez M, Raju GC, Hooi SC: Inhibition of histone deacetylase 2 increases apoptosis and p21Cip1/WAF1 expression, independent of histone deacetylase 1. Cell Death Differ. 2005, 12 (4): 395-404. 10.1038/sj.cdd.4401567.CrossRefPubMed
15.
Hrzenjak A, Moinfar F, Kremser ML, Strohmeier B, Staber PB, Zatloukal K, Denk H: Valproate inhibition of histone deacetylase 2 affects differentiation and decreases proliferation of endometrial stromal sarcoma cells. Mol Cancer Ther. 2006, 5 (9): 2203-2210. 10.1158/1535-7163.MCT-05-0480.CrossRefPubMed
16.
Sideri M, Jones RW, Wilkinson EJ, Preti M, Heller DS, Scurry J, Haefner H, Neill S: Squamous vulvar intraepithelial neoplasia: 2004 modified terminology, ISSVD Vulvar Oncology Subcommittee. J Reprod Med. 2005, 50 (11): 807-810.PubMed
17.
Kononen J, Bubendorf L, Kallioniemi A, Barlund M, Schraml P, Leighton S, Torhorst J, Mihatsch MJ, Sauter G, Kallioniemi OP: Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med. 1998, 4 (7): 844-847. 10.1038/nm0798-844.CrossRefPubMed
18.
Sano T, Oyama T, Kashiwabara K, Fukuda T, Nakajima T: Immunohistochemical overexpression of p16 protein associated with intact retinoblastoma protein expression in cervical cancer and cervical intraepithelial neoplasia. Pathol Int. 1998, 48 (8): 580-585. 10.1111/j.1440-1827.1998.tb03954.x.CrossRefPubMed
19.
Santos M, Montagut C, Mellado B, Garcia A, Ramon y Cajal S, Cardesa A, Puig-Tintore LM, Ordi J: Immunohistochemical staining for p16 and p53 in premalignant and malignant epithelial lesions of the vulva. Int J Gynecol Pathol. 2004, 23 (3): 206-214. 10.1097/01.pgp.0000130108.03231.89.CrossRefPubMed
20.
Riethdorf S, Neffen EF, Cviko A, Loning T, Crum CP, Riethdorf L: p16INK4A expression as biomarker for HPV 16-related vulvar neoplasias. Hum Pathol. 2004, 35 (12): 1477-1483. 10.1016/j.humpath.2004.09.004.CrossRefPubMed
21.
Santos M, Landolfi S, Olivella A, Lloveras B, Klaustermeier J, Suarez H, Alos L, Puig-Tintore LM, Campo E, Ordi J: p16 overexpression identifies HPV-positive vulvar squamous cell carcinomas. Am J Surg Pathol. 2006, 30 (11): 1347-1356. 10.1097/01.pas.0000213251.82940.bf.CrossRefPubMed
22.
Biedermann K, Dandachi N, Trattner M, Vogl G, Doppelmayr H, More E, Staudach A, Dietze O, Hauser-Kronberger C: Comparison of real-time PCR signal-amplified in situ hybridization and conventional PCR for detection and quantification of human papillomavirus in archival cervical cancer tissue. J Clin Microbiol. 2004, 42 (8): 3758-3765. 10.1128/JCM.42.8.3758-3765.2004.CrossRefPubMedPubMedCentral
23.
O'Neill CJ, McCluggage WG: p16 expression in the female genital tract and its value in diagnosis. Adv Anat Pathol. 2006, 13 (1): 8-15. 10.1097/01.pap.0000201828.92719.f3.CrossRefPubMed
24.
Scholzen T, Gerdes J: The Ki-67 protein: from the known and the unknown. J Cell Physiol. 2000, 182 (3): 311-322. 10.1002/(SICI)1097-4652(200003)182:3<311::AID-JCP1>3.0.CO;2-9.CrossRefPubMed
25.
Weichert W, Roske A, Gekeler V, Beckers T, Ebert MP, Pross M, Dietel M, Denkert C, Rocken C: Association of patterns of class I histone deacetylase expression with patient prognosis in gastric cancer: a retrospective analysis. Lancet Oncol. 2008, 9 (2): 139-148. 10.1016/S1470-2045(08)70004-4.CrossRefPubMed
26.
Marks P, Rifkind RA, Richon VM, Breslow R, Miller T, Kelly WK: Histone deacetylases and cancer: causes and therapies. Nat Rev Cancer. 2001, 1 (3): 194-202. 10.1038/35106079.CrossRefPubMed
27.
Weichert W, Roske A, Gekeler V, Beckers T, Stephan C, Jung K, Fritzsche FR, Niesporek S, Denkert C, Dietel M, et al: Histone deacetylases 1, 2 and 3 are highly expressed in prostate cancer and HDAC2 expression is associated with shorter PSA relapse time after radical prostatectomy. Br J Cancer. 2008, 98 (3): 604-610. 10.1038/sj.bjc.6604199.CrossRefPubMedPubMedCentral
28.
Weichert W, Roske A, Niesporek S, Noske A, Buckendahl AC, Dietel M, Gekeler V, Boehm M, Beckers T, Denkert C: Class I histone deacetylase expression has independent prognostic impact in human colorectal cancer: specific role of class I histone deacetylases in vitro and in vivo. Clin Cancer Res. 2008, 14 (6): 1669-1677. 10.1158/1078-0432.CCR-07-0990.CrossRefPubMed
29.
Munster PN, Troso-Sandoval T, Rosen N, Rifkind R, Marks PA, Richon VM: The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces differentiation of human breast cancer cells. Cancer Res. 2001, 61 (23): 8492-8497.PubMed
30.
Imesch P, Fink D, Fedier A: Romidepsin reduces histone deacetylase activity, induces acetylation of histones, inhibits proliferation, and activates apoptosis in immortalized epithelial endometriotic cells. Fertil Steril. 2010
31.
Li X, Chen BD: Histone Deacetylase Inhibitor M344 Inhibits Cell Proliferation and Induces Apoptosis in Human THP-1 Leukemia Cells. Am J Biomed Sci. 2009, 1 (4): 352-363.CrossRefPubMedPubMedCentral
32.
Hrzenjak A, Moinfar F, Kremser ML, Strohmeier B, Petru E, Zatloukal K, Denk H: Histone deacetylase inhibitor vorinostat suppresses the growth of uterine sarcomas in vitro and in vivo. Mol Cancer. 2010, 9: 49-10.1186/1476-4598-9-49.CrossRefPubMedPubMedCentral
33.
Tan J, Cang S, Ma Y, Petrillo RL, Liu D: Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents. J Hematol Oncol. 2010, 3: 5-10.1186/1756-8722-3-5.CrossRefPubMedPubMedCentral
34.
Kim J, Guan J, Chang I, Chen X, Han D, Wang CY: PS-341 and histone deacetylase inhibitor synergistically induce apoptosis in head and neck squamous cell carcinoma cells. Mol Cancer Ther. 9 (7): 1977-1984.
35.
Shen J, Huang C, Jiang L, Gao F, Wang Z, Zhang Y, Bai J, Zhou H, Chen Q: Enhancement of cisplatin induced apoptosis by suberoylanilide hydroxamic acid in human oral squamous cell carcinoma cell lines. Biochem Pharmacol. 2007, 73 (12): 1901-1909. 10.1016/j.bcp.2007.03.009.CrossRefPubMed
36.
Chung YL, Lee MY, Pui NN: Epigenetic therapy using the histone deacetylase inhibitor for increasing therapeutic gain in oral cancer: prevention of radiation-induced oral mucositis and inhibition of chemical-induced oral carcinogenesis. Carcinogenesis. 2009, 30 (8): 1387-1397. 10.1093/carcin/bgp079.CrossRefPubMed
37.
Murakami J, Asaumi J, Kawai N, Tsujigiwa H, Yanagi Y, Nagatsuka H, Inoue T, Kokeguchi S, Kawasaki S, Kuroda M, et al: Effects of histone deacetylase inhibitor FR901228 on the expression level of telomerase reverse transcriptase in oral cancer. Cancer Chemother Pharmacol. 2005, 56 (1): 22-28. 10.1007/s00280-004-0976-x.CrossRefPubMed
Metadata
Title
Expression pattern of class I histone deacetylases in vulvar intraepithelial neoplasia and vulvar cancer: a tissue microarray study
Authors
Nicolas Samartzis
Patrick Imesch
Konstantin J Dedes
Eleftherios P Samartzis
André Fedier
Daniel Fink
Rosmarie Caduff
Mathias K Fehr
Publication date
01-12-2011
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2011
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-11-463

Other articles of this Issue 1/2011

BMC Cancer 1/2011 Go to the issue

Study protocol

Treatment of malignant sinonasal tumours with intensity-modulated radiotherapy (IMRT) and carbon ion boost (C12)

Research article

Healthcare costs in women with metastatic breast cancer receiving chemotherapy as their principal treatment modality

Erratum

Erratum to:Prognostic significance of fascin expression in advanced colorectal cancer: an immunohistochemical study of colorectal adenomas and adenocarcinomas

Research article

Acceptance of oral chemotherapy in breast cancer patients - a survey study

Research article

The HOPE fixation technique - a promising alternative to common prostate cancer biobanking approaches

Research article

Oxidative stress and antioxidant status in primary bone and soft tissue sarcoma
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits